JCBio appointed for Korea; Tekon Biotech appointed for China provide access to liver and small-intestine NAM screening with “molecules in, data out” speed and human relevanceSAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim Labs”), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today announced it has signed JCBio as an authorized distributor in Korea and Tekon Biotech as an authorized distributor in China for it ...

Financial Performance - The company's LTM 2025 revenue was approximately $40237 billion, with the DSA segment contributing 6001%[13,74] - The company expects to deliver approximately $295 million in cumulative, annualized cost savings by 2026[48] - The company's capital expenditures represented 51% of LTM revenue, compared to a peak of 82% in 2022[54] - Approximately $450 million in stock repurchases were made in 2024-2025[54] Market Position and Strategy - The company supported over 80% of FDA-approved novel drugs in the last five years (2021-2025)[11] - The company estimates the addressable market opportunity to be approximately $25 billion[11] - The company's revenue from the biopharma industry is approximately 70%[9] - The company plans to divest underperforming or non-core assets representing approximately 7% of 2025E revenue[52] Acquisitions and Outlook - The company plans to acquire K.F. (Cambodia) Ltd for approximately $510 million, expected to close in early Q1 2026[53] - The company plans to acquire the remaining 79% equity stake of PathoQuest SAS for approximately $60 million, expected to close by the end of Q1 2026[53] - PathoQuest is expected to generate $15-$20 million in 2026 annual revenue[53]

Core Insights - The Biologics X 3DCC Summit 2026 is a significant event merging two influential scientific conferences in India, focusing on biopharmaceutical product development and advances in 3D cell culture [1][2] Event Overview - The summit will take place on January 22-23, 2026, at Novotel Dona Sylvia Resort, Goa, India, and is expected to attract over 800 global leaders in biologics, biosimilars, and cell-based technologies [1][2] Purpose of Merging Events - The integration of Biologics and 3DCC aims to address adoption bottlenecks in advanced 3D cell culture technologies for developing monoclonal antibodies, cell and gene therapies, and other next-generation modalities [3][4] Industry Collaboration - The summit will facilitate cross-sector dialogue and collaboration, promoting large-scale implementation of innovative therapies and enhancing accessibility in the biopharma industry [4][6] Regulatory Alignment - The event is timely as global regulators, including the US FDA, are increasingly adopting human-relevant, non-animal testing models, helping Indian stakeholders align with these trends [5][6] Conference Features - The two-day conference will include pre-conference workshops, three parallel scientific tracks focusing on 3D cell culture and biologics, poster sessions for early-career researchers, and a startup innovation showcase [7][11] Networking and Collaboration Opportunities - Participants will have the chance to gain insights, forge strategic collaborations, and engage in curated networking opportunities tailored for partnerships and policy discussions [8][11] Call to Action - The summit invites scientists, innovators, and leaders to contribute to shaping the future of biopharma in India, emphasizing the shift towards novel biologics and non-animal testing models [8][9]

Financial Performance & Strategic Review - Charles River's Board supports the company's strategic direction, focusing on strengthening its scientific portfolio, divesting underperforming assets, maximizing financial performance, and maintaining disciplined capital deployment[7] - The company is refining its portfolio by selling certain underperforming or non-core businesses, representing approximately 7% of the estimated 2025 revenue[9] - These divestitures are expected to result in non-GAAP earnings per share accretion of at least $0.30 on an annualized basis once completed, excluding reinvestment benefits or interest expense impacts[9] - A new $1.0 billion stock repurchase authorization was approved by the Board in October, replacing a previous authorization under which $450.7 million in common stock had been repurchased since August 2024[10] 3Q25 Results & Updated Guidance - 3Q25 revenue was $1,004.9 million, a 0.5% decrease compared to $1,009.8 million in 3Q24, with a 1.6% organic revenue decline[13] - The GAAP EPS for 3Q25 was $1.10, a 17.3% decrease from $1.33 in 3Q24, while the non-GAAP EPS was $2.43, a 6.2% decrease from $2.59[15] - The company revised its 2025 revenue growth guidance to a decline of 1.5%-0.5% reported and a decline of 2.5%-1.5% organic[16] - The 2025 non-GAAP EPS estimate is now $10.10-$10.30, which includes a $0.10 guidance improvement at the midpoint[36] Segment Performance & Outlook - DSA (Discovery and Safety Assessment) revenue for 3Q25 was $600.7 million, a 2.3% decrease compared to $615.1 million in 3Q24, with a 3.1% organic revenue decline[17] - RMS (Research Models and Services) revenue for 3Q25 was $213.5 million, a 7.9% increase compared to $197.8 million in 3Q24, with a 6.5% organic revenue growth[25] - Manufacturing revenue for 3Q25 was $190.7 million, a 3.1% decrease compared to $196.9 million in 3Q24, with a 5.1% organic revenue decline[28]